All Stories

  1. WarpDemuX-custom - Multiplexed sequence-specific direct RNA sequencing of ribosomal RNA and beyond

    Article • October 2026, openRxiv

    Max von Kleist

  2. Global immuno-epidemiology and the persistence of mpox clade IIb in MSM

    Article • September 2026, openRxiv

    Max von Kleist, Alexander Bartel

  3. Global immuno-epidemiology and the persistence of mpox clade IIb in MSM

    Article • September 2026, Springer Science + Business Media

    Max von Kleist

  4. Author Correction: Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men

    Article • Nature Communications, May 2026, Springer Science + Business Media

    Max von Kleist

  5. Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in men who have sex with men

    Article • Nature Communications, May 2026, Springer Science + Business Media

    Max von Kleist

  6. Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Against HIV

    Article • CPT Pharmacometrics & Systems Pharmacology, April 2026, Wiley

    Max von Kleist

  7. SIMPLICITY is an agent-based, multi-scale mathematical model to study SARS-CoV-2 intra- and between-host evolution

    Article • Communications Biology, January 2026, Springer Science + Business Media

    Max von Kleist

  8. Behavior change and infection induced immunity led to the decline of the 2022 Mpox outbreak in Berlin

    Article • Communications Medicine, January 2026, Springer Science + Business Media

    Max von Kleist

  9. Pharmacological markers of HIV prevention for oral pre-exposure prophylaxis in MSM

    Article • December 2025, Springer Science + Business Media

    Max von Kleist

  10. Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIV

    Article • August 2025, Cold Spring Harbor Laboratory Press

    Max von Kleist

  11. Atypical Influenza A(H3N2) Activity Patterns in Germany, 2021–2023, and Characterization of Newly Emerged Virus Clades

    Article • Journal of Medical Virology, August 2025, Wiley

    Max von Kleist

  12. Non-cell autonomous control of presynaptic remodeling by the hypothalamic autophagy/NPY axis

    Article • June 2025, Cold Spring Harbor Laboratory Press

    Max von Kleist

  13. Efficient and accurate simulation of infectious diseases on adaptive networks

    Article • PLOS Complex Systems, June 2025, PLOS

    Max von Kleist

  14. Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone

    Article • Journal of the International AIDS Society, June 2025, Wiley

    Max von Kleist

  15. Sequential and independent probabilistic events regulate differential axon targeting during development in Drosophila melanogaster

    Article • Nature Neuroscience, May 2025, Springer Science + Business Media

    Max von Kleist, Dr. Alexandre Dumoulin

  16. Demultiplexing and barcode-specific adaptive sampling for nanopore direct RNA sequencing

    Article • Nature Communications, April 2025, Springer Science + Business Media

    Max von Kleist

  17. Native epitranscriptome sequencing reveals Hepatitis B virus RNA stability protected by heavy m6A modification

    Article • April 2025, Cold Spring Harbor Laboratory Press

    Max von Kleist

  18. Efficient and accurate simulation of infectious diseases on adaptive networks

    Article • December 2024, Cold Spring Harbor Laboratory Press

    Max von Kleist

  19. Demultiplexing and barcode-specific adaptive sampling for nanopore direct RNA sequencing

    Article • September 2024, Springer Science + Business Media

    Max von Kleist

  20. Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant

    Article • CPT Pharmacometrics & Systems Pharmacology, August 2024, Wiley

    Max von Kleist

  21. Modelling the impact of initiation delay, duration and prior PrEP usage on the prophylactic efficacy of FTC/TDF-containing post-exposure prophylaxis

    Article • July 2024, Cold Spring Harbor Laboratory Press

    Max von Kleist

  22. Multi-Input data ASsembly for joint Analysis (MIASA): A framework for the joint analysis of disjoint sets of variables

    Article • PLOS One, May 2024, PLOS

    Max von Kleist

  23. Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subdermal implant

    Article • April 2024, Cold Spring Harbor Laboratory Press

    Max von Kleist

  24. Axonal self-sorting without target guidance in Drosophila visual map formation

    Article • Science, March 2024, American Association for the Advancement of Science

    Max von Kleist

  25. Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women

    Article • Nature Medicine, November 2023, Springer Science + Business Media

    Max von Kleist

  26. SARS-CoV-2 Evolution on a Dynamic Immune Landscape

    Article • October 2023, Research Square

    Max von Kleist

  27. T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual

    Article • Microorganisms, June 2023, MDPI AG

    Max von Kleist

  28. Sequencing accuracy and systematic errors in nanopore direct RNA sequencing

    Article • March 2023, Cold Spring Harbor Laboratory Press

    Max von Kleist

  29. Leveraging Secondary Data for Global Health Digitalization

    Article • The Lancet Digital Health, February 2023, Elsevier

    Max von Kleist

  30. Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021

    Article • Clinical Infectious Diseases, June 2022, Oxford University Press (OUP)

    Max von Kleist

  31. Short- and long-range interactions in the HIV-1 5′ UTR regulate genome dimerization and packaging

    Article • Nature Structural & Molecular Biology, March 2022, Springer Science + Business Media

    Max von Kleist

  32. Investigation of a Limited but Explosive COVID-19 Outbreak in a German Secondary School

    Article • Viruses, January 2022, MDPI AG

    Max von Kleist

  33. S̲tochastic S̲imulation A̲lgorithm For Effective Spreading Dynamics On T̲ime-Evolving A̲daptive N̲etworX̲ (SSATAN-X)

    Article • Mathematical Modelling of Natural Phenomena, January 2022, EDP Sciences

    Max von Kleist

  34. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes

    Article • PLoS Computational Biology, December 2021, PLOS

    Max von Kleist

  35. Brain connectivity inversely scales with developmental temperature in Drosophila

    Article • Cell Reports, December 2021, Elsevier

    Max von Kleist

  36. Stochastic Simulation Algorithm for effective spreading dynamics on Time-evolving Adaptive NetworX (SSATAN-X)

    Article • November 2021, Cold Spring Harbor Laboratory Press

    Max von Kleist

  37. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020

    Article • Nature Communications, October 2021, Springer Science + Business Media

    Max von Kleist

  38. Inferring gene regulatory networks from single-cell RNA-seq temporal snapshot data requires higher-order moments

    Article • Patterns, September 2021, Elsevier

    Max von Kleist

  39. Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany

    Article • Viruses, July 2021, MDPI AG

    Max von Kleist

  40. Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes

    Article • July 2021, Cold Spring Harbor Laboratory Press

    Max von Kleist

  41. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV

    Article • Viruses, July 2021, MDPI AG

    Max von Kleist

  42. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data

    Article • The Lancet Regional Health - Europe, July 2021, Elsevier

    Max von Kleist

  43. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020

    Article • May 2021, Research Square

    Max von Kleist

  44. Rapid incidence estimation from SARS-CoV-2 genomes reveals decreased case detection in Europe during summer 2020

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Max von Kleist

  45. Variable brain wiring through scalable and relative synapse formation in Drosophila

    Article • May 2021, Cold Spring Harbor Laboratory Press

    Max von Kleist

  46. ITN—VIROINF: Understanding (Harmful) Virus-Host Interactions by Linking Virology and Bioinformatics

    Article • Viruses, April 2021, MDPI AG

    Max von Kleist

  47. On the Sufficient Condition for Solving the Gap-Filling Problem Using Deep Convolutional Neural Networks

    Article • IEEE Transactions on Neural Networks and Learning Systems, January 2021, Institute of Electrical & Electronics Engineers (IEEE)

    Max von Kleist

  48. COVIDStrategyCalculator: A standalone software to assess testing- and quarantine strategies for incoming travelers, contact person management and de-isolation

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Max von Kleist

  49. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research

    Article • Briefings in Bioinformatics, November 2020, Oxford University Press (OUP)

    Dr Anton Petrov, Max von Kleist

  50. Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV

    Article • Frontiers in Pharmacology, August 2020, Frontiers

    Max von Kleist

  51. Local c-di-GMP Signaling in the Control of Synthesis of the E. coli Biofilm Exopolysaccharide pEtN-Cellulose

    Article • Journal of Molecular Biology, July 2020, Elsevier

    Max von Kleist

  52. Autophagy-dependent filopodial kinetics restrict synaptic partner choice during Drosophila brain wiring

    Article • Nature Communications, March 2020, Springer Science + Business Media

    Max von Kleist

  53. Serial Synapse Formation through Filopodial Competition for Synaptic Seeding Factors

    Article • Developmental Cell, August 2019, Elsevier

    Max von Kleist

  54. SLCV–a supervised learning—computer vision combined strategy for automated muscle fibre detection in cross-sectional images

    Article • PeerJ, July 2019, PeerJ

    Max von Kleist

  55. Discerning the spatio-temporal disease patterns of surgically induced OA mouse models

    Article • PLOS One, April 2019, PLOS

    Max von Kleist

  56. Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany

    Article • Journal of Virology, April 2019, ASM Journals

    Max von Kleist

  57. The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis

    Article • Frontiers in Pharmacology, March 2019, Frontiers

    Max von Kleist

  58. Analysis of long non-coding RNA and mRNA expression in bovine macrophages brings up novel aspects of Mycobacterium avium subspecies paratuberculosis infections

    Article • Scientific Reports, February 2019, Springer Science + Business Media

    Max von Kleist

  59. Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

    Article • PLoS Computational Biology, January 2019, PLOS

    Max von Kleist

  60. Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

    Article • PLoS Computational Biology, June 2018, PLOS

    Max von Kleist

  61. In cell mutational interference mapping experiment (in cell MIME) identifies the 5′ polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging

    Article • Nucleic Acids Research, March 2018, Oxford University Press (OUP)

    Max von Kleist

  62. Statistical Analysis of the First Passage Path Ensemble of Jump Processes

    Article • Journal of Statistical Physics, December 2017, Springer Science + Business Media

    Max von Kleist

  63. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors

    Article • Virology Journal, November 2017, Springer Science + Business Media

    Max von Kleist

  64. In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements

    Article • Toxicology in Vitro, June 2017, Elsevier

    Max von Kleist

  65. Inferring HIV-1 Transmission Dynamics in Germany From Recently Transmitted Viruses

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, November 2016, Wolters Kluwer Health

    Max von Kleist

  66. Top-down and bottom-up models for nucleoside reverse transcriptase inhibitors against HIV-1

    Article • European Journal of Pharmaceutical Sciences, October 2016, Elsevier

    Max von Kleist, Mr Sulav Duwal

  67. MIMEAnTo: profiling functional RNA in mutational interference mapping experiments

    Article • Bioinformatics, July 2016, Oxford University Press (OUP)

    Max von Kleist

  68. Systems-pharmacology modelling pipeline for PrEP against HIV-1

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2016, Wiley

    Max von Kleist, Mr Sulav Duwal

  69. Coupling cellular phenotype and mechanics to understand extracellular matrix formation and homeostasis in osteoarthritis * *financial support through BMBF project OVERLOAD-PrevOp, grant number 01EC1408H is acknowledged.

    Article • IFAC-PapersOnLine, January 2016, Elsevier

    Max von Kleist

  70. Mutational interference mapping experiment (MIME) for studying RNA structure and function

    Article • Nature Chemical Biology, August 2015, Nature

    Max von Kleist

  71. Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Escherichia coli

    Article • BMC Systems Biology, July 2015, Springer Science + Business Media

    Max von Kleist

  72. Optimal Treatment Strategies in the Context of ‘Treatment for Prevention’ against HIV-1 in Resource-Poor Settings

    Article • PLoS Computational Biology, April 2015, PLOS

    Max von Kleist, Mr Sulav Duwal

  73. Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany

    Article • Journal of the International AIDS Society, November 2014, Wiley

    Max von Kleist

  74. Assessment of Ambiguous Base Calls in HIV-1 pol Population Sequences as a Biomarker for Identification of Recent Infections in HIV-1 Incidence Studies

    Article • Journal of Clinical Microbiology, June 2014, ASM Journals

    Max von Kleist

  75. Awareness and Utilization of Reporting Pathways for Adverse Events Following Immunization: Online Survey Among Pediatricians in Russia and Germany

    Article • Pediatric Drugs, May 2014, Springer Science + Business Media

    Max von Kleist

  76. 'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays

    Article • QJM, April 2014, Oxford University Press (OUP)

    Max von Kleist

  77. Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care

    Article • PLOS One, March 2014, PLOS

    Max von Kleist

  78. Markov control processes with rare state observation: theory and application to treatment scheduling in HIV–1

    Article • Communications in Mathematical Sciences, January 2014, International Press of Boston

    Max von Kleist

  79. Towards a Personalised Approach to Managing Influenza Infections in Infants and Children – Food for Thought and a Note on Oseltamivir

    Article • Infectious Disorders - Drug Targets, June 2013, Bentham Science Publishers

    Max von Kleist

  80. In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis

    Article • PLOS One, April 2013, PLOS

    Max von Kleist

  81. Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis

    Article • BMC Infectious Diseases, January 2013, Springer Science + Business Media

    Max von Kleist

  82. Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses

    Article • The Pediatric Infectious Disease Journal, September 2012, Wolters Kluwer Health

    Max von Kleist

  83. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenofovir and Prophylactic Efficacy against HIV-1 Infection

    Article • PLOS One, July 2012, PLOS

    Max von Kleist, Mr Sulav Duwal

  84. HIV-1 Polymerase Inhibition by Nucleoside Analogs: Cellular- and Kinetic Parameters of Efficacy, Susceptibility and Resistance Selection

    Article • PLoS Computational Biology, January 2012, PLOS

    Max von Kleist

  85. Quantifying the Impact of Nevirapine-Based Prophylaxis Strategies To Prevent Mother-to-Child Transmission of HIV-1: a Combined Pharmacokinetic, Pharmacodynamic, and Viral Dynamic Analysis To Predict Clinical Outcomes

    Article • Antimicrobial Agents and Chemotherapy, September 2011, ASM Journals

    Max von Kleist

  86. HIV Quasispecies Dynamics during Pro-Active Treatment Switching: Impact on Multi-Drug Resistance and Resistance Archiving in Latent Reservoirs

    Article • PLOS One, March 2011, PLOS

    Max von Kleist

  87. Drug-Class Specific Impact of Antivirals on the Reproductive Capacity of HIV

    Article • PLoS Computational Biology, March 2010, PLOS

    Max von Kleist

  88. Pharmacokinetic–pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine

    Article • European Journal of Pharmaceutical Sciences, March 2009, Elsevier

    Max von Kleist

  89. Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution

    Article • Journal of Pharmacokinetics and Pharmacodynamics, September 2007, Springer Science + Business Media

    Max von Kleist

  90. Software Supported Modelling in Pharmacokinetics

    Article • January 2006, Springer Science + Business Media

    Max von Kleist

  91. Update on Antiviral DNA Vaccine Research (2000–2003)

    Article • January 2004, Wiley

    Max von Kleist